Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93.1M
-
Number of holders
-
240
-
Total 13F shares, excl. options
-
74.6M
-
Shares change
-
-515K
-
Total reported value, excl. options
-
$2.56B
-
Value change
-
-$23.6M
-
Put/Call ratio
-
0.71
-
Number of buys
-
124
-
Number of sells
-
-99
-
Price
-
$34.34
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q4 2017
286 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q4 2017.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 240 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.6M shares
of 93.1M outstanding shares and own 80.09% of the company stock.
Largest 10 shareholders include BlackRock Inc. (10.1M shares), BAILLIE GIFFORD & CO (9.63M shares), Vanguard Group Inc (7.22M shares), D. E. Shaw & Co., Inc. (4.76M shares), DIMENSIONAL FUND ADVISORS LP (3.53M shares), STATE STREET CORP (3.48M shares), THRIVENT FINANCIAL FOR LUTHERANS (2.81M shares), ACADIAN ASSET MANAGEMENT LLC (2.21M shares), FRONTIER CAPITAL MANAGEMENT CO LLC (1.96M shares), and NORTHERN TRUST CORP (1.65M shares).
This table shows the top 240 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.